Lutetium Lu-177 Vipivotide Tetraxetan
Also known as: Pluvicto, 177Lu-PSMA-617
Pluvicto is a PSMA-targeted radioligand treatment for selected metastatic prostate-cancer populations. PSMA PET selection, specialist radiopharmaceutical administration and radiation precautions are integral to treatment.
Quick Facts
Identity and targeting
LutetiumLu-177 vipivotide tetraxetan, also called 177Lu-PSMA-617 and marketed as Pluvicto, links a PSMA-targeting ligand with radioactive lutetium-177. It was initially US-approved in 2022 for advanced prostate cancer expressing the target.
PSMA binding and radiation delivery
PSMA on prostate-cancer cells binds the ligand. Attached lutetium-177 emits short-range beta particles that damage DNA in target-bearing cancer and nearby tissue while limiting more distant exposure. A PSMA PET scan confirms target expression before selection.
VISION found improved imaging-based progression-free survival and overall survival when the radioligand was added to standard care in men whose disease had progressed after hormonal and chemotherapy treatment. Those results concern that treatment setting and do not imply benefit without target selection.
Sources: [1]
Approval expansion and administration
| Year | Product-specific approval context |
|---|---|
| 2022 | PSMA-positive metastatic castration-resistant prostate cancer after hormone therapy and taxane chemotherapy. |
| 2025 | Broadened to patients without prior chemotherapy. |
| 2026 | Added combination with a hormone-blocking medicine for metastatic disease still responsive to hormone therapy. |
Use requires PSMA-positive metastatic prostate cancer, with the hormonal-treatment context matching the indication. Specialized centers administer IV infusions, up to six cycles approximately six weeks apart, with radiopharmaceutical handling capability.
Adverse effects and precautions
Common effects include fatigue, dry mouth, nausea, reduced appetite, anemia and constipation. Important risks include bone-marrow suppression, renal toxicity, radiation exposure and fertility effects. Patients receive precautions to protect others from radiation; these requirements distinguish treatment from an ordinary injectable peptide.
References and further reading
This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .
- 10.1056/NEJMoa2107322PSMA binding and radiation deliveryCited in: PSMA binding and radiation delivery
- novartis.comApproval expansion and administrationCited in: Approval expansion and administration
- accessdata.fda.govApproval expansion and administrationCited in: Approval expansion and administration
Frequently Asked Questions About Lutetium Lu-177 Vipivotide Tetraxetan
Related Peptides
Continue exploring Lutetium Lu-177 Vipivotide Tetraxetan
Search all related references →Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.